BVS · Bioventus Inc.
$11.81
+0.33 (+2.87%)
At close · Jul 24
Market Cap
$985.71M
Shares
83.53M
Bioventus Inc. Earnings Call Transcripts
Every quarterly earnings call for Bioventus Inc. (BVS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲27.8%
$140.33M
−$7.25M
'22 Q2
22-08-11
▲18.2%
$128.66M
−$108.25M
'22 Q3
22-11-08
▼3.5%
$125.83M
−$31.93M
'22 Q4
23-03-31
▲1.5%
$119.06M
−$139.15M
'23 Q1
23-05-16
▼2.3%
$137.07M
−$3.68M
'23 Q2
23-08-08
▼6.1%
$120.79M
−$7.30M
'23 Q3
23-11-07
▲7.6%
$135.42M
−$6.10M
'23 Q4
24-03-12
▲8.7%
$129.46M
−$4.57M
'24 Q1
24-05-07
▲10.3%
$151.22M
−$23.99M
'24 Q2
24-08-06
▲15%
$138.96M
−$4.82M
'24 Q3
24-11-05
▲13.5%
$153.64M
−$156,000
'24 Q4
25-03-11
▼4.3%
$123.88M
−$2.64M
'25 Q1
25-05-06
▼2.4%
$147.66M
$7.46M
'25 Q2
25-08-06
▼0.2%
$138.65M
$3.15M
'25 Q3
25-11-04
▲2.8%
$157.90M
$14.76M
'25 Q4
26-03-05
LATEST
▲6.6%
$132.09M
$3.11M
'26 Q1
26-05-06
Conference
Investor event
2026-06-08
Goldman Sachs Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Bioventus Inc. Q1 FY2026 Earnings Call
Confident tone
Revenue growth and investment acceleration
PNS business ramp-up
Cash flow and balance sheet
Revenue
$132.09M
▲ 6.6% YoY Diluted EPS
$0.04
Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Bioventus Inc. Q4 FY2025 Earnings Call
Confident tone
PNS growth driver
Ultrasonics business
Profitability expansion
Revenue
$157.90M*
▲ 2.8% YoY Gross margin
68.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Bioventus Inc. Q3 FY2025 Earnings Call
Confident tone
Organic revenue growth and portfolio momentum
Profitability and EBITDA margin expansion
Pain treatments and surgical solutions (P&S) core business
Revenue
$138.65M
▼ 0.2% YoY Diluted EPS
$0.05
Gross margin
68.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Bioventus Inc. Q2 FY2025 Earnings Call
Positive tone
Full-year guidance reiteration
Ultrasonics growth
Tariffs and FX headwinds
Revenue
$147.66M
▼ 2.4% YoY Diluted EPS
$0.11
Gross margin
69.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Bioventus Inc. Q1 FY2025 Earnings Call
Positive tone
Profitability and Cash Flow
Pain Treatments / DUROLANE
Surgical Solutions / Ultrasonics
Revenue
$123.88M
▼ 4.3% YoY Diluted EPS
$-0.04
Gross margin
67.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Bioventus Inc. Q4 FY2024 Earnings Call
Confident tone
2024 Financial Performance
International Expansion
Exogen Restorative Therapy Turnaround
Revenue
$153.64M*
▲ 13.5% YoY Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Bioventus Inc. Q3 FY2024 Earnings Call
Confident tone
Profitability / Margin Expansion
Revenue Growth
Surgical Solutions / Ultronics
Revenue
$138.96M
▲ 15% YoY Diluted EPS
$-0.07
Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Bioventus Inc. Q2 FY2024 Earnings Call
Confident tone
Liquidity and leverage reduction
Revenue growth and double-digit organic performance
Surgical Solutions and Ultrasonics franchise
Revenue
$151.22M
▲ 10.3% YoY Diluted EPS
$-0.37
Gross margin
68.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Bioventus Inc. Q1 FY2024 Earnings Call
Confident tone
Surgical Solutions momentum
HA / Durolane growth
Guidance and outlook
Revenue
$129.46M
▲ 8.7% YoY Diluted EPS
$-0.07
Gross margin
68.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
Bioventus Inc. Q4 FY2023 Earnings Call
Positive tone
Cash flow and leverage
Revenue growth acceleration
HA / Pain Treatment portfolio (DUROLANE, GELSYN, SUPARTZ)
Revenue
$135.42M*
▲ 7.6% YoY Gross margin
63.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Bioventus Inc. Q3 FY2023 Earnings Call
Revenue
$120.79M
▼ 6.1% YoY Diluted EPS
$-0.12
Gross margin
65.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Bioventus Inc. Q2 FY2023 Earnings Call
Revenue
$137.07M
▼ 2.3% YoY Diluted EPS
$-0.06
Gross margin
65.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-16
Bioventus Inc. Q1 FY2023 Earnings Call
Revenue
$119.06M
▲ 1.5% YoY Diluted EPS
$-2.24
Gross margin
62.1%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
Bioventus Inc. Q4 FY2022 Earnings Call
Revenue
$125.83M*
▼ 3.5% YoY Gross margin
59.0%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Bioventus Inc. Q3 FY2022 Earnings Call
Revenue
$128.66M
▲ 18.2% YoY Diluted EPS
$-1.76
Gross margin
65.7%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Bioventus Inc. Q2 FY2022 Earnings Call
Revenue
$140.33M
▲ 27.8% YoY Diluted EPS
$-0.11
Gross margin
68.9%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Bioventus Inc. Q1 FY2022 Earnings Call
Revenue
$117.29M
▲ 43.4% YoY Diluted EPS
$-0.19
Gross margin
64.5%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Bioventus Inc. Q4 FY2021 Earnings Call
Revenue
$130.41M*
Gross margin
67.3%
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Bioventus Inc. Q3 FY2021 Earnings Call
Revenue
$108.89M
Diluted EPS
$-0.03
Gross margin
72.6%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Bioventus Inc. Q2 FY2021 Earnings Call
Revenue
$109.82M
Diluted EPS
$-0.10
Gross margin
69.5%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Bioventus Inc. Q1 FY2021 Earnings Call
Revenue
$81.78M
Diluted EPS
$-0.02
Gross margin
72.8%
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Bioventus Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–23 of 23 earnings calls
Key facts
CIK
1665988
CUSIP
09075A108
13F (30d)
16 filings
16 filers
Visit website
Investor relations